David Portman

David Portman

Company: Sermonix Pharmaceuticals

Job title: Chief Executive Officer, Chief Medical Officer


From the Clinic to CDx: Navigating the Path of Clinical Trial Assay Selection & CDx Options for Targeted Oncology Therapies in Mid-Stage Development 11:30 am

Describe how an optimal clinical trial assay may be selected and discuss reimbursement, dual marketing plans Explain significant risk and non-significant risk determination, IDE and pre-Sub issues Understand how aspects of a biomarker assay impact recruitment, study execution (including defining a clinical cut off strategy), and transition to a CDx and PMA and transition to…Read more

day: Track B - Day 1 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.